Cancer research
A new study published in the Cancer Treatment and Research Communications journal has found that a biosimilar version of bevacizumab, known as CT-P16, has equivalent long-term efficacy to the European-approved reference bevacizumab in patients with metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC). Researchers at the Clinical Hospital Center
Cancer research
Research presented in a Phase II clinical trial has demonstrated that retifanlimab, a humanized monoclonal antibody targeting programmed cell death protein-1 (PD-1), can induce frequent and durable responses in chemotherapy-naive patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC). The study, known as POD1UM-201, enrolled 101 patients across
Cancer research
DelveInsight's report, "Recurrent or Metastatic Head and Neck Cancer Pipeline Insight 2025", provides a comprehensive analysis of the pipeline landscape for this devastating disease. As of August 2025, 40+ companies and 40+ pipeline drugs are actively being developed to treat recurrent or metastatic head and neck
Cancer research
Researchers from Sichuan University in Chengdu, People's Republic of China, have developed and evaluated a radiomics-based machine learning model to differentiate between lung squamous cell carcinoma (SCC) and adenocarcinoma (AC) in patients with brain metastases (BMs). The study used T1-enhanced magnetic resonance imaging (MRI) features and identified 833
Cancer
A new study published in Frontiers in Oncology suggests that perioperative anesthesia management plays a crucial role in preventing postoperative cancer recurrence and metastasis. The study, conducted by researchers at the School of Anesthesiology in Shandong, People's Republic of China, highlights the immunosuppressive effects of certain anesthesia techniques
Cancer
Researchers from the University of Texas MD Anderson Cancer Center have developed a machine learning model that improves survival in advanced non-small cell lung cancer (NSCLC) patients. The model, called A-STEP, uses clinicogenomic data from four cohorts to predict individual benefit from adding chemotherapy to immunotherapy. The study found that
Cancer
Investigators at Dokuz Eylul University Faculty of Medicine have conducted a study comparing the International metastatic renal cell carcinoma (mRCC) Database Consortium (IMDC), Memorial Sloan Kettering Cancer Center (MSKCC), and Cleveland Clinic Foundation (CCF) risk models in patients with metastatic renal cell cancer who received immunotherapy (IO) and molecular targeted
Cancer
Research from Technical University Munich has identified heat shock protein 70 (Hsp70) as a potential biomarker for thoracic cancer, particularly for lymph node metastases and early relapse. According to the study published in BMC Cancer, Hsp70 is overexpressed in many cancer types and is present on the plasma membrane of
Cancer research
Researchers at Nanchang University have made a groundbreaking discovery in the fight against gastric cancer. According to a recent study, the ubiquitin-proteasome system (UPS) plays a crucial role in regulating tumorigenesis and development. Specifically, the ubiquitination factor E4B (UBE4B/UFD2) has been shown to be associated with the development of
Cancer research
A recent substudy of the ENZA-p trial has evaluated the prognostic value of baseline PSMA-PET parameters in patients with metastatic castration-resistant prostate cancer. The research, led by St Vincent's Hospital, has found that quantitative parameters derived from gallium-68 [Ga]Ga-prostate-specific membrane antigen (PSMA)-11 PET-CT, such as whole-body
Cancer research
Researchers have made significant progress in understanding the treatment of adrenocortical carcinoma, a rare and aggressive form of cancer. A study published in Nature Communications has identified delta-like non-canonical Notch ligand 1 (DLK1) as a cell surface protein with high expression in multiple refractory adult metastatic cancers, including small cell
Cancer research
In a groundbreaking study on mice, researchers have discovered that common respiratory infections, such as COVID, the flu, and other viral infections, can re-awaken dormant breast cancer cells, leading to a surge in cancer activity. This finding has significant implications for breast cancer survivors, as it suggests that protecting themselves
